Neuroendocrine Carcinoma (Carcinoid) Clinical Trial
Official title:
Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples
The goal of this study is to compare several methods for measurement of Chromogranin A in
their ability to serve as a marker for disease activity in patients with neuroendocrine
tumors.
Further, in a subgroup, we will determine if taking a proton pump inhibitor affects
Chromogranin A levels.
Patient group: patients with neuroendocrine tumors (active or inactive) Healthy volunteers ;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic